24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO...
Uložené v:
| Vydané v: | The Lancet global health Ročník 13; číslo 2; s. e355 - e363 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Elsevier Ltd
01.02.2025
|
| Predmet: | |
| ISSN: | 2214-109X, 2214-109X |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO rifampicin-resistant tuberculosis treatment guidelines, countries are facing difficult decisions about when and how to incorporate new drug regimens into national guidelines. We aimed to assess the probability of BPaL-based regimens being cost-saving using data collected in the TB-PRACTECAL trial.
This economic evaluation using a cost-utility analysis was embedded in five TB-PRACTECAL trial sites in Belarus, Uzbekistan, and South Africa. Between Nov 19, 2020, and Sept 27, 2022, we collected detailed primary unit cost data in six hospitals and four ambulatory health facilities and collected data on patient-incurred costs from 73 trial participants. The primary efficacy endpoint of the main trial, a composite of unfavourable outcomes (death, disease recurrence, treatment failure, early discontinuation of therapy, withdrawal, or loss to follow-up) and clinically important safety outcomes by 72 weeks of follow-up were incorporated into the analysis. Societal perspective cost data and effect outcome data were input into a Markov model to estimate the cost per disability-adjusted life-year (DALY) averted by BPaL-based regimens compared with the standard of care over a 20-year time horizon. We conducted a range of univariate and probabilistic sensitivity analyses to test our findings.
BPaL-based regimens averted a mean of 1·28 DALYs and saved a mean of US$14 868 (SD 291) per person from the provider perspective compared with standard-of-care regimens over 20 years. Patient-incurred costs were reduced by a mean of $172 (SD 0·84) in BPaL-based regimen groups compared with standard of care. The main cost drivers for both providers and patients were inpatient bed-days; the duration of the inpatient period varied across countries. Varying a range of model parameters affected the degree of cost savings but did not change the finding that BPaL-based regimens are cost-saving compared with standard of care.
This trial-based evidence adds to consistent indications from modelling studies that BPaL-based regimens are cost-saving for both the patient and health system. Urgent implementation of BPaL-based regimens in countries with a high burden of tuberculosis could improve treatment of rifampicin-resistant tuberculosis, reduce pill burden, and free up desperately needed resources within the health system.
Médecins Sans Frontières. |
|---|---|
| AbstractList | New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO rifampicin-resistant tuberculosis treatment guidelines, countries are facing difficult decisions about when and how to incorporate new drug regimens into national guidelines. We aimed to assess the probability of BPaL-based regimens being cost-saving using data collected in the TB-PRACTECAL trial.
This economic evaluation using a cost-utility analysis was embedded in five TB-PRACTECAL trial sites in Belarus, Uzbekistan, and South Africa. Between Nov 19, 2020, and Sept 27, 2022, we collected detailed primary unit cost data in six hospitals and four ambulatory health facilities and collected data on patient-incurred costs from 73 trial participants. The primary efficacy endpoint of the main trial, a composite of unfavourable outcomes (death, disease recurrence, treatment failure, early discontinuation of therapy, withdrawal, or loss to follow-up) and clinically important safety outcomes by 72 weeks of follow-up were incorporated into the analysis. Societal perspective cost data and effect outcome data were input into a Markov model to estimate the cost per disability-adjusted life-year (DALY) averted by BPaL-based regimens compared with the standard of care over a 20-year time horizon. We conducted a range of univariate and probabilistic sensitivity analyses to test our findings.
BPaL-based regimens averted a mean of 1·28 DALYs and saved a mean of US$14 868 (SD 291) per person from the provider perspective compared with standard-of-care regimens over 20 years. Patient-incurred costs were reduced by a mean of $172 (SD 0·84) in BPaL-based regimen groups compared with standard of care. The main cost drivers for both providers and patients were inpatient bed-days; the duration of the inpatient period varied across countries. Varying a range of model parameters affected the degree of cost savings but did not change the finding that BPaL-based regimens are cost-saving compared with standard of care.
This trial-based evidence adds to consistent indications from modelling studies that BPaL-based regimens are cost-saving for both the patient and health system. Urgent implementation of BPaL-based regimens in countries with a high burden of tuberculosis could improve treatment of rifampicin-resistant tuberculosis, reduce pill burden, and free up desperately needed resources within the health system.
Médecins Sans Frontières. New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO rifampicin-resistant tuberculosis treatment guidelines, countries are facing difficult decisions about when and how to incorporate new drug regimens into national guidelines. We aimed to assess the probability of BPaL-based regimens being cost-saving using data collected in the TB-PRACTECAL trial.BACKGROUNDNew 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO rifampicin-resistant tuberculosis treatment guidelines, countries are facing difficult decisions about when and how to incorporate new drug regimens into national guidelines. We aimed to assess the probability of BPaL-based regimens being cost-saving using data collected in the TB-PRACTECAL trial.This economic evaluation using a cost-utility analysis was embedded in five TB-PRACTECAL trial sites in Belarus, Uzbekistan, and South Africa. Between Nov 19, 2020, and Sept 27, 2022, we collected detailed primary unit cost data in six hospitals and four ambulatory health facilities and collected data on patient-incurred costs from 73 trial participants. The primary efficacy endpoint of the main trial, a composite of unfavourable outcomes (death, disease recurrence, treatment failure, early discontinuation of therapy, withdrawal, or loss to follow-up) and clinically important safety outcomes by 72 weeks of follow-up were incorporated into the analysis. Societal perspective cost data and effect outcome data were input into a Markov model to estimate the cost per disability-adjusted life-year (DALY) averted by BPaL-based regimens compared with the standard of care over a 20-year time horizon. We conducted a range of univariate and probabilistic sensitivity analyses to test our findings.METHODSThis economic evaluation using a cost-utility analysis was embedded in five TB-PRACTECAL trial sites in Belarus, Uzbekistan, and South Africa. Between Nov 19, 2020, and Sept 27, 2022, we collected detailed primary unit cost data in six hospitals and four ambulatory health facilities and collected data on patient-incurred costs from 73 trial participants. The primary efficacy endpoint of the main trial, a composite of unfavourable outcomes (death, disease recurrence, treatment failure, early discontinuation of therapy, withdrawal, or loss to follow-up) and clinically important safety outcomes by 72 weeks of follow-up were incorporated into the analysis. Societal perspective cost data and effect outcome data were input into a Markov model to estimate the cost per disability-adjusted life-year (DALY) averted by BPaL-based regimens compared with the standard of care over a 20-year time horizon. We conducted a range of univariate and probabilistic sensitivity analyses to test our findings.BPaL-based regimens averted a mean of 1·28 DALYs and saved a mean of US$14 868 (SD 291) per person from the provider perspective compared with standard-of-care regimens over 20 years. Patient-incurred costs were reduced by a mean of $172 (SD 0·84) in BPaL-based regimen groups compared with standard of care. The main cost drivers for both providers and patients were inpatient bed-days; the duration of the inpatient period varied across countries. Varying a range of model parameters affected the degree of cost savings but did not change the finding that BPaL-based regimens are cost-saving compared with standard of care.FINDINGSBPaL-based regimens averted a mean of 1·28 DALYs and saved a mean of US$14 868 (SD 291) per person from the provider perspective compared with standard-of-care regimens over 20 years. Patient-incurred costs were reduced by a mean of $172 (SD 0·84) in BPaL-based regimen groups compared with standard of care. The main cost drivers for both providers and patients were inpatient bed-days; the duration of the inpatient period varied across countries. Varying a range of model parameters affected the degree of cost savings but did not change the finding that BPaL-based regimens are cost-saving compared with standard of care.This trial-based evidence adds to consistent indications from modelling studies that BPaL-based regimens are cost-saving for both the patient and health system. Urgent implementation of BPaL-based regimens in countries with a high burden of tuberculosis could improve treatment of rifampicin-resistant tuberculosis, reduce pill burden, and free up desperately needed resources within the health system.INTERPRETATIONThis trial-based evidence adds to consistent indications from modelling studies that BPaL-based regimens are cost-saving for both the patient and health system. Urgent implementation of BPaL-based regimens in countries with a high burden of tuberculosis could improve treatment of rifampicin-resistant tuberculosis, reduce pill burden, and free up desperately needed resources within the health system.Médecins Sans Frontières.FUNDINGMédecins Sans Frontières. |
| Author | Singh, Maninder Pal Dodd, Matthew Kazounis, Emil Nyangweso, George Mokua Samieva, Nazgul Parpieva, Nargiza Motta, Ilaria Nyang'wa, Bern-Thomas Jolivet, Pascal Laurence, Yoko V Berry, Catherine Moe, Soe Moodliar, Ronelle Sweeney, Sedona Fielding, Katherine Solodovnikova, Varvara Abdrasuliev, Tleubergen Aw, Pei Sun Tigay, Zinaida Rassool, Mohammed Usmanova, Ruzilya Liverko, Irina Butabekov, Ilhomjon |
| Author_xml | – sequence: 1 givenname: Sedona surname: Sweeney fullname: Sweeney, Sedona email: sedona.sweeney@lshtm.ac.uk organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 2 givenname: Yoko V surname: Laurence fullname: Laurence, Yoko V organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 3 givenname: Catherine surname: Berry fullname: Berry, Catherine organization: Public Health Department OCA, Médecins Sans Frontières, London, UK – sequence: 4 givenname: Maninder Pal surname: Singh fullname: Singh, Maninder Pal organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 5 givenname: Matthew surname: Dodd fullname: Dodd, Matthew organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 6 givenname: Katherine surname: Fielding fullname: Fielding, Katherine organization: London School of Hygiene & Tropical Medicine, London, UK – sequence: 7 givenname: Emil surname: Kazounis fullname: Kazounis, Emil organization: Public Health Department OCA, Médecins Sans Frontières, London, UK – sequence: 8 givenname: Ronelle surname: Moodliar fullname: Moodliar, Ronelle organization: Tuberculosis & HIV Investigative Network, Durban, South Africa – sequence: 9 givenname: Varvara surname: Solodovnikova fullname: Solodovnikova, Varvara organization: Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus – sequence: 10 givenname: Zinaida surname: Tigay fullname: Tigay, Zinaida organization: Republican Phthisiological Hospital #2, Nukus, Uzbekistan – sequence: 11 givenname: Irina surname: Liverko fullname: Liverko, Irina organization: Republican Specialised Scientific Practical Medical Centre of Phthisiology and Pulmonology, Tashkent, Uzbekistan – sequence: 12 givenname: Nargiza surname: Parpieva fullname: Parpieva, Nargiza organization: Republican Specialised Scientific Practical Medical Centre of Phthisiology and Pulmonology, Tashkent, Uzbekistan – sequence: 13 givenname: Ilhomjon surname: Butabekov fullname: Butabekov, Ilhomjon organization: Republican Specialised Scientific Practical Medical Centre of Phthisiology and Pulmonology, Tashkent, Uzbekistan – sequence: 14 givenname: Ruzilya surname: Usmanova fullname: Usmanova, Ruzilya organization: Republican Specialised Scientific Practical Medical Centre of Phthisiology and Pulmonology, Tashkent, Uzbekistan – sequence: 15 givenname: Mohammed surname: Rassool fullname: Rassool, Mohammed organization: Wits Health Consortium, Johannesburg, South Africa – sequence: 16 givenname: Ilaria surname: Motta fullname: Motta, Ilaria organization: Public Health Department OCA, Médecins Sans Frontières, London, UK – sequence: 17 givenname: George Mokua surname: Nyangweso fullname: Nyangweso, George Mokua organization: Drugs for Neglected Diseases Initiative, Nairobi, Kenya – sequence: 18 givenname: Pascal surname: Jolivet fullname: Jolivet, Pascal organization: Public Health Department OCA, Médecins Sans Frontières, London, UK – sequence: 19 givenname: Tleubergen surname: Abdrasuliev fullname: Abdrasuliev, Tleubergen organization: Médecins Sans Frontières, Tashkent, Uzbekistan – sequence: 20 givenname: Soe surname: Moe fullname: Moe, Soe organization: Médecins Sans Frontières, Tashkent, Uzbekistan – sequence: 21 givenname: Pei Sun surname: Aw fullname: Aw, Pei Sun organization: Médecins Sans Frontières, Tashkent, Uzbekistan – sequence: 22 givenname: Nazgul surname: Samieva fullname: Samieva, Nazgul organization: Médecins Sans Frontières, Tashkent, Uzbekistan – sequence: 23 givenname: Bern-Thomas surname: Nyang'wa fullname: Nyang'wa, Bern-Thomas organization: London School of Hygiene & Tropical Medicine, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39890235$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU9rFTEUxYNUbK39CEqWFRxNMklmRhGpj_oHCoq-hbuQydyRazPJM8lUuvGzO32vFumm3k0ul3N-kHMekr0QAxDymLPnnHH94qsQXFacdd-OhXzKmNRNJe-Rg5vz3j_7PjnK-Qdbputq0TQPyH7dtR0TtTogv4WsfgGcP6PW-yom62mC7zhByHSMiW5mP8Vg0yVNONppgw5DlSBjLjYUWuYekpt9XA4UA12_rT5_OVmtT1cnZ7QkXHAZC-SX1AYKLoY4oaNwYf1sC8bwiNwfrc9wdP0ekvW70_XqQ3X26f3HhVE5qXWpnBqElMI13MpeK971lg2gW6dap60APSrJQHV175qxFjCIRjejUE7aUXBVH5LjHXaT4s8ZcjETZgfe2wBxzqbmWqhGtKpdpE-upXM_wWA2Cafl--ZvZItA7QQuxZwTjDcSzsxVO2bbjrmK3ghptu0Yufhe3fI5LNsQSrLo73S_2blhSekCIZnsEIKDARO4YoaIdxJe3yI4jwGd9edw-R_-P7MFvM8 |
| CitedBy_id | crossref_primary_10_1128_msphere_00513_25 |
| Cites_doi | 10.1371/journal.pgph.0001337 10.1093/cid/ciu186 10.5588/ijtld.17.0661 10.1136/bmjopen-2021-051521 10.1016/S2213-2600(20)30039-4 10.1016/j.jval.2016.04.015 10.1016/S2213-2600(23)00389-2 10.1080/14787210.2020.1742109 10.1186/s13063-022-06331-8 10.5588/ijtld.23.0163 10.1136/bmjopen-2019-036599 10.1371/journal.pone.0296448 10.1093/heapol/16.3.326 10.1016/j.jval.2021.11.1351 10.1086/588292 10.1016/j.ijid.2023.03.013 10.1371/journal.pmed.1004401 10.1056/NEJMoa2119430 10.1136/bmjgh-2021-007182 10.1186/s13690-016-0147-7 |
| ContentType | Journal Article |
| Copyright | 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S2214-109X(24)00467-4 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 2214-109X |
| EndPage | e363 |
| ExternalDocumentID | 39890235 10_1016_S2214_109X_24_00467_4 S2214109X24004674 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | South Africa |
| GeographicLocations_xml | – name: South Africa |
| GrantInformation | Médecins Sans Frontières. |
| GroupedDBID | .1- .FO 0R~ 1P~ 457 53G AAEDT AAEDW AAIKJ AALRI AAMRU AAXUO AAYWO ABMAC ACGFS ACHQT ACVFH ADBBV ADCNI ADEZE ADVLN AENEX AEUPX AEVXI AEXQZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP BAWUL BCNDV DIK EBS EJD FDB GROUPED_DOAJ HZ~ IPNFZ IXB KQ8 M41 M~E O9- OD. OK1 OO~ RIG ROL SSZ Z5R 6I. AACTN AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c466t-c5d2442c71a4b6519ba0de68c58c6a2e6f540e593bc7f32ed2767f25c4af2153 |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001422026800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2214-109X |
| IngestDate | Wed Oct 01 13:50:31 EDT 2025 Thu Jul 10 06:32:37 EDT 2025 Tue Nov 18 21:55:33 EST 2025 Sat Nov 29 07:57:25 EST 2025 Sat May 03 15:56:12 EDT 2025 Tue Aug 26 16:35:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c466t-c5d2442c71a4b6519ba0de68c58c6a2e6f540e593bc7f32ed2767f25c4af2153 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S2214109X24004674 |
| PMID | 39890235 |
| PQID | 3162572858 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3162572858 pubmed_primary_39890235 crossref_primary_10_1016_S2214_109X_24_00467_4 crossref_citationtrail_10_1016_S2214_109X_24_00467_4 elsevier_sciencedirect_doi_10_1016_S2214_109X_24_00467_4 elsevier_clinicalkey_doi_10_1016_S2214_109X_24_00467_4 |
| PublicationCentury | 2000 |
| PublicationDate | February 2025 2025-02-00 20250201 |
| PublicationDateYYYYMMDD | 2025-02-01 |
| PublicationDate_xml | – month: 02 year: 2025 text: February 2025 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The Lancet global health |
| PublicationTitleAlternate | Lancet Glob Health |
| PublicationYear | 2025 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Schnippel, Firnhaber, Berhanu, Page-Shipp, Sinanovic (bib22) 2018; 22 Wadman (bib35) Berry, du Cros, Fielding (bib5) 2022; 23 Franke, Appleton, Bayona (bib17) 2008; 46 Cunnama, Garcia Baena, Laurence (bib20) 2019 James, Klaassen, Sweeney (bib33) 2024; 21 Fekadu, Wang, You (bib34) 2024; 28 Hilderink, Plasmans, Snijders, Boshuizen, Poos, van Gool (bib30) 2016; 74 Quaife, Houben, Allwood (bib28) 2020; 8 bib31 Wilkinson, Sculpher, Claxton (bib13) 2016; 19 (bib1) 2024 Fox-Rushby, Hanson (bib26) 2001; 16 (bib16) 2022 Babaniyazov, Nyang'wa, Pardington, Stringer (bib7) 2016 Gupta, Juneja, Babawale (bib32) 2024; 19 Naidoo, Dookie (bib15) (bib24) 2021 Mpobela Agnarson, Williams, Kambili, Mattson, Metz (bib9) 2020; 18 Nyang'wa, Berry, Kazounis (bib4) 2024; 12 Mulder, Rupert, Setiawan (bib12) 2022; 7 bib25 Conradie, Bagdasaryan, Borisov (bib3) 2022; 387 bib23 (bib29) Nov 14, 2016 Husereau, Drummond, Augustovski (bib8) 2022; 25 Marx, Dunbar, Enarson (bib14) 2014; 58 (bib2) 2022 Gomez, Siapka, Conradie (bib10) 2021; 11 bib18 (bib27) 2019 (bib19) 2017 Vanino, Granozzi, Akkerman (bib36) 2023; 130 Sweeney, Berry, Kazounis (bib11) 2022; 2 Sweeney, Cunnama, Laurence (bib21) Sweeney, Gomez, Kitson (bib6) 2020; 10 James (10.1016/S2214-109X(24)00467-4_bib33) 2024; 21 Babaniyazov (10.1016/S2214-109X(24)00467-4_bib7) Sweeney (10.1016/S2214-109X(24)00467-4_bib11) 2022; 2 Quaife (10.1016/S2214-109X(24)00467-4_bib28) 2020; 8 Sweeney (10.1016/S2214-109X(24)00467-4_bib21) Gomez (10.1016/S2214-109X(24)00467-4_bib10) 2021; 11 Mulder (10.1016/S2214-109X(24)00467-4_bib12) 2022; 7 Naidoo (10.1016/S2214-109X(24)00467-4_bib15) Schnippel (10.1016/S2214-109X(24)00467-4_bib22) 2018; 22 (10.1016/S2214-109X(24)00467-4_bib19) 2017 Fox-Rushby (10.1016/S2214-109X(24)00467-4_bib26) 2001; 16 Fekadu (10.1016/S2214-109X(24)00467-4_bib34) 2024; 28 Vanino (10.1016/S2214-109X(24)00467-4_bib36) 2023; 130 Nyang'wa (10.1016/S2214-109X(24)00467-4_bib4) 2024; 12 Sweeney (10.1016/S2214-109X(24)00467-4_bib6) 2020; 10 Marx (10.1016/S2214-109X(24)00467-4_bib14) 2014; 58 (10.1016/S2214-109X(24)00467-4_bib1) 2024 Wadman (10.1016/S2214-109X(24)00467-4_bib35) Franke (10.1016/S2214-109X(24)00467-4_bib17) 2008; 46 Husereau (10.1016/S2214-109X(24)00467-4_bib8) 2022; 25 (10.1016/S2214-109X(24)00467-4_bib24) 2021 Mpobela Agnarson (10.1016/S2214-109X(24)00467-4_bib9) 2020; 18 Cunnama (10.1016/S2214-109X(24)00467-4_bib20) 2019 Wilkinson (10.1016/S2214-109X(24)00467-4_bib13) 2016; 19 Hilderink (10.1016/S2214-109X(24)00467-4_bib30) 2016; 74 Gupta (10.1016/S2214-109X(24)00467-4_bib32) 2024; 19 Berry (10.1016/S2214-109X(24)00467-4_bib5) 2022; 23 Conradie (10.1016/S2214-109X(24)00467-4_bib3) 2022; 387 |
| References_xml | – volume: 19 year: 2024 ident: bib32 article-title: Global adoption of 6-month drug-resistant TB regimens: projected uptake by 2026 publication-title: PLoS One – year: 2022 ident: bib2 article-title: WHO consolidated guidelines on tuberculosis – year: 2022 ident: bib16 article-title: Global tuberculosis report – year: 2016 ident: bib7 article-title: 'Trial and Error’ operational reflections on the set-up of a community engagement programme for a phase ii/iii clinical trial to identify new MDR-TB treatments in Uzbekistan. Médecins Sans Frontières Scientific Day South Asia – volume: 28 start-page: 81 year: 2024 end-page: 85 ident: bib34 article-title: Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting publication-title: Int J Tuberc Lung Dis – volume: 7 year: 2022 ident: bib12 article-title: Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis publication-title: BMJ Glob Health – volume: 58 start-page: 1676 year: 2014 end-page: 1683 ident: bib14 article-title: The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study publication-title: Clin Infect Dis – volume: 21 year: 2024 ident: bib33 article-title: Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: a mathematical modeling analysis publication-title: PLoS Med – year: Nov 14, 2016 ident: bib29 article-title: MSF TB severity grading scale version 5.0 – volume: 10 year: 2020 ident: bib6 article-title: Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy publication-title: BMJ Open – volume: 46 start-page: 1844 year: 2008 end-page: 1851 ident: bib17 article-title: Risk factors and mortality associated with default from multidrug-resistant tuberculosis publication-title: Clin Infect Dis – volume: 19 start-page: 921 year: 2016 end-page: 928 ident: bib13 article-title: The International Decision Support Initiative reference case for economic evaluation: an aid to thought publication-title: Value Health – year: 2019 ident: bib27 article-title: Global Burden of Disease Study disability weights – ident: bib35 article-title: Major drug company bends in battle over access to key TB treatment. Science – volume: 18 start-page: 475 year: 2020 end-page: 483 ident: bib9 article-title: The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa publication-title: Expert Rev Anti Infect Ther – volume: 74 start-page: 37 year: 2016 ident: bib30 article-title: Accounting for multimorbidity can affect the estimation of the Burden of Disease: a comparison of approaches publication-title: Arch Public Health – ident: bib31 article-title: Real interest rate (%) – volume: 23 start-page: 484 year: 2022 ident: bib5 article-title: TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis publication-title: Trials – ident: bib18 article-title: Average monthly earnings of employees by sex and occupation – volume: 22 start-page: 393 year: 2018 end-page: 398 ident: bib22 article-title: Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa publication-title: Int J Tuberc Lung Dis – volume: 25 start-page: 3 year: 2022 end-page: 9 ident: bib8 article-title: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations publication-title: Value Health – volume: 387 start-page: 810 year: 2022 end-page: 823 ident: bib3 article-title: Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis publication-title: N Engl J Med – volume: 130 start-page: S12 year: 2023 end-page: S15 ident: bib36 article-title: Update of drug-resistant tuberculosis treatment guidelines: a turning point publication-title: Int J Infect Dis – ident: bib15 article-title: Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors – ident: bib25 article-title: Consumer price index (CPI) databases – volume: 8 start-page: 332 year: 2020 end-page: 333 ident: bib28 article-title: Post-tuberculosis mortality and morbidity: valuing the hidden epidemic publication-title: Lancet Respir Med – volume: 16 start-page: 326 year: 2001 end-page: 331 ident: bib26 article-title: Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis publication-title: Health Policy Plan – year: 2019 ident: bib20 article-title: Costing guidelines for tuberculosis interventions – volume: 2 year: 2022 ident: bib11 article-title: Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis publication-title: PLOS Glob Public Health – year: 2021 ident: bib24 article-title: Medicines catalog October 2021 – year: 2024 ident: bib1 article-title: Global tuberculosis report 2024 – volume: 12 start-page: 117 year: 2024 end-page: 128 ident: bib4 article-title: Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B–3, multi-arm, multicentre, non-inferiority trial publication-title: Lancet Respir Med – volume: 11 year: 2021 ident: bib10 article-title: Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines publication-title: BMJ Open – ident: bib21 article-title: Value TB dataset: costs per intervention – year: 2017 ident: bib19 article-title: Tuberculosis patient cost surveys: a handbook – ident: bib23 article-title: Adult bags—body bags – volume: 2 year: 2022 ident: 10.1016/S2214-109X(24)00467-4_bib11 article-title: Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis publication-title: PLOS Glob Public Health doi: 10.1371/journal.pgph.0001337 – volume: 58 start-page: 1676 year: 2014 ident: 10.1016/S2214-109X(24)00467-4_bib14 article-title: The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study publication-title: Clin Infect Dis doi: 10.1093/cid/ciu186 – volume: 22 start-page: 393 year: 2018 ident: 10.1016/S2214-109X(24)00467-4_bib22 article-title: Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.17.0661 – year: 2017 ident: 10.1016/S2214-109X(24)00467-4_bib19 – volume: 11 year: 2021 ident: 10.1016/S2214-109X(24)00467-4_bib10 article-title: Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines publication-title: BMJ Open doi: 10.1136/bmjopen-2021-051521 – volume: 8 start-page: 332 year: 2020 ident: 10.1016/S2214-109X(24)00467-4_bib28 article-title: Post-tuberculosis mortality and morbidity: valuing the hidden epidemic publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30039-4 – volume: 19 start-page: 921 year: 2016 ident: 10.1016/S2214-109X(24)00467-4_bib13 article-title: The International Decision Support Initiative reference case for economic evaluation: an aid to thought publication-title: Value Health doi: 10.1016/j.jval.2016.04.015 – ident: 10.1016/S2214-109X(24)00467-4_bib15 – year: 2021 ident: 10.1016/S2214-109X(24)00467-4_bib24 – volume: 12 start-page: 117 year: 2024 ident: 10.1016/S2214-109X(24)00467-4_bib4 article-title: Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B–3, multi-arm, multicentre, non-inferiority trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(23)00389-2 – volume: 18 start-page: 475 year: 2020 ident: 10.1016/S2214-109X(24)00467-4_bib9 article-title: The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa publication-title: Expert Rev Anti Infect Ther doi: 10.1080/14787210.2020.1742109 – ident: 10.1016/S2214-109X(24)00467-4_bib35 – volume: 23 start-page: 484 year: 2022 ident: 10.1016/S2214-109X(24)00467-4_bib5 publication-title: Trials doi: 10.1186/s13063-022-06331-8 – volume: 28 start-page: 81 year: 2024 ident: 10.1016/S2214-109X(24)00467-4_bib34 article-title: Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.23.0163 – volume: 10 year: 2020 ident: 10.1016/S2214-109X(24)00467-4_bib6 article-title: Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy publication-title: BMJ Open doi: 10.1136/bmjopen-2019-036599 – year: 2019 ident: 10.1016/S2214-109X(24)00467-4_bib20 – volume: 19 year: 2024 ident: 10.1016/S2214-109X(24)00467-4_bib32 article-title: Global adoption of 6-month drug-resistant TB regimens: projected uptake by 2026 publication-title: PLoS One doi: 10.1371/journal.pone.0296448 – volume: 16 start-page: 326 year: 2001 ident: 10.1016/S2214-109X(24)00467-4_bib26 article-title: Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis publication-title: Health Policy Plan doi: 10.1093/heapol/16.3.326 – volume: 25 start-page: 3 year: 2022 ident: 10.1016/S2214-109X(24)00467-4_bib8 article-title: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations publication-title: Value Health doi: 10.1016/j.jval.2021.11.1351 – volume: 46 start-page: 1844 year: 2008 ident: 10.1016/S2214-109X(24)00467-4_bib17 article-title: Risk factors and mortality associated with default from multidrug-resistant tuberculosis publication-title: Clin Infect Dis doi: 10.1086/588292 – volume: 130 start-page: S12 issue: suppl 1 year: 2023 ident: 10.1016/S2214-109X(24)00467-4_bib36 article-title: Update of drug-resistant tuberculosis treatment guidelines: a turning point publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2023.03.013 – ident: 10.1016/S2214-109X(24)00467-4_bib7 – volume: 21 year: 2024 ident: 10.1016/S2214-109X(24)00467-4_bib33 article-title: Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: a mathematical modeling analysis publication-title: PLoS Med doi: 10.1371/journal.pmed.1004401 – volume: 387 start-page: 810 year: 2022 ident: 10.1016/S2214-109X(24)00467-4_bib3 article-title: Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis publication-title: N Engl J Med doi: 10.1056/NEJMoa2119430 – volume: 7 year: 2022 ident: 10.1016/S2214-109X(24)00467-4_bib12 article-title: Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis publication-title: BMJ Glob Health doi: 10.1136/bmjgh-2021-007182 – year: 2024 ident: 10.1016/S2214-109X(24)00467-4_bib1 – ident: 10.1016/S2214-109X(24)00467-4_bib21 – volume: 74 start-page: 37 year: 2016 ident: 10.1016/S2214-109X(24)00467-4_bib30 article-title: Accounting for multimorbidity can affect the estimation of the Burden of Disease: a comparison of approaches publication-title: Arch Public Health doi: 10.1186/s13690-016-0147-7 |
| SSID | ssj0000993277 |
| Score | 2.3799443 |
| Snippet | New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e355 |
| SubjectTerms | Administration, Oral Adult Antitubercular Agents - administration & dosage Antitubercular Agents - economics Antitubercular Agents - therapeutic use Cost-Benefit Analysis Diarylquinolines - economics Diarylquinolines - therapeutic use Drug Therapy, Combination Female Humans Male Quality-Adjusted Life Years Rifampin - therapeutic use South Africa Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - economics Tuberculosis, Pulmonary - drug therapy |
| Title | 24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2214109X24004674 https://dx.doi.org/10.1016/S2214-109X(24)00467-4 https://www.ncbi.nlm.nih.gov/pubmed/39890235 https://www.proquest.com/docview/3162572858 |
| Volume | 13 |
| WOSCitedRecordID | wos001422026800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2214-109X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000993277 issn: 2214-109X databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELa2hQMSQrxZHpWRAIHawMZxEodbW23FoSwVBGlvkeM4YkXqLOlu6an_jP_G2E68QbTqcuASrSJNssl8mYc93wxCL_xRXhARCY8leenRCD7F3I-F55dUsqAICsK4GTYRTyZsOk2OBoNfHRfmtIqVYmdnyfy_qhrOgbI1dfYf1O0uCifgNygdjqB2OK6leEK9n1IaI8eryjMMfD1-4RgSVlNUOF9W8Gd0tVwzK_nxXO-te5B160hSLbYXy1w2YlnVulXJTG2ne97R5939dKwbJ9ghH3rH2ZTSgXGQLbO51ze8H_BqGFqeddd7xDIv3cqOrhJrC85kUSvnJTRhW1sd4yPq7_WqGndPNnbv37EX3cXAD3-zDCSl20A2ECBX_XUNEnal0J35I8Sn4CTMoF3wVBec6-x30MMp6RljGdgOwH95Cbtg8cVdDWJ5Ql-SRC8WxC3p6I_O3JNP2cHXw8MsHU_TV_Mfnh5apl91O8FlA10jcZjoisKP56slPgi-A2Jmf7o7rThk71a3f03om_bWl0VHl2U_JgpKb6NbbfqCdy3s7qCBVHfRTbv2iy2l7R46byG4gzsA4g6AGACIHQDxRQDEfQDimcJ9AGIDQGwA-B5zhTv44RX87qP0YJzuf_DaOR-eAOOw8ERYQJBJROxzmkeQUuR8VMiIiZCJiBMZlZBWyDAJchGXAZEFiaO4JKGgvISINXiANlWt5COEA17QUQEieSQoRObcjyTk7CHhecwSkQ8R7V5vJtoe-HoUS5W5YketFV2WMc0IzYxWMjpEb53Y3DaBuUog6nSXdQxn8MkZAPAqQeYE2xDYhrbriD7vQJKBi9D7flzJenmSBX4EjpmwkA3RQ4se9xhBogsNgvDxGtJP0I3Vh_oUbS6apXyGrovTxeyk2UIb8ZRtmS_gN9Wk4ZQ |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=24-week%2C+all-oral+regimens+for+pulmonary+rifampicin-resistant+tuberculosis+in+TB-PRACTECAL+trial+sites%3A+an+economic+evaluation&rft.jtitle=The+Lancet+global+health&rft.au=Sweeney%2C+Sedona&rft.au=Laurence%2C+Yoko+V&rft.au=Berry%2C+Catherine&rft.au=Singh%2C+Maninder+Pal&rft.date=2025-02-01&rft.issn=2214-109X&rft.eissn=2214-109X&rft.volume=13&rft.issue=2&rft.spage=e355&rft_id=info:doi/10.1016%2FS2214-109X%2824%2900467-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2214-109X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2214-109X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2214-109X&client=summon |